Advertisement

Advertisement

2022 San Antonio Breast Cancer Symposium

breast cancer

Yara Abdou, MD, on Race and Clinical Outcomes in the RxPONDER Breast Cancer Trial

Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breas...

Breast Cancer
Immunotherapy

T-DXd Yields Superior Outcomes Over Chemotherapy-Based Regimens in Patients Previously Treated With T-DM1: DESTINY-Breast02

Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic...

T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03

Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastati...

Breast Cancer
Immunotherapy

Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer

Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% with...

Breast Cancer

First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer

In patients with hormone receptor–positive, HER2-negative advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events a...

Breast Cancer

Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy

Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of dis...

Breast Cancer

Genomic Assay May Predict Long-Term Prognosis in Premenopausal Patients With Hormone Receptor–Positive Early-Stage Breast Cancer

Among premenopausal patients with hormone receptor–positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on the Breast Cancer Index genomic assay had an increased ris...

Breast Cancer

Black Patients With Breast Cancer May Have Worse Outcomes Than Other Patients Despite Similar Genetic Recurrence Scores

Non-Hispanic Black patients with lymph node–positive, hormone receptor (HR)–positive/HER2-negative breast cancer experienced worse outcomes compared with the outcomes of non-Hispanic White, Asian, and...

Advertisement

Advertisement



Advertisement